同济医学院海外校友风采——汪尔佳

姓名/职位/现工作单位

Erjia Wang, MS, MD (汪尔佳）

Associate Principal Scientist

770 Sumneytown Pike

Merck Research Lab

Office WP45-3124

West Point, PA 19486,USA

同济医学院求学与工作经历：

1983-1986 硕士研究生，导师刘俊杰

1986-1991 协和医院麻醉科主治医生

2015-2016 海外校友总会主席

联系方式：

Email：erjiawangmd@gmail.com

微信 (WeChat): Wangson-2

校友简介:

Dr. Erjia Wang is an experienced pharmaceutical scientist at Merck Research Lab, Toxicology Division, West Point, Pennsylvania. His research mainly focuses on preclinical drug development: drug candidate safety assessments, drug transport and metabolism assessments, hepatic enzyme induction or inhibition and metabolic profiling evaluation. He is particularly interested in development of safety biomarkers and tumor diagnostic biomarkers through RNA in situ hybridization platforms. He is a respected team member of several FDA approved drugs.Examples include antihistamine drugs Claritin and Clarinex; anti-fungus drug Posaconazole; cholesterol modulation drugs Zetia and Vytorin; antivirus drug Zepatier, and cancer immunotherapy drug Keytruda. He has published more than one hundred original articles and scientific reports as well as 2 drug patents. Dr. Wang has actively involved in activities and services of Tongji Medical College Overseas Association and had been the past president for this organization. His broad personal interests include gardening, deep sea fishing, traveling, scientific writing, tennis instruction as well as investing of pharma and biotech companies.

汪尔佳医学博士，美国默沙东药物研究所新药研发资深硏究员。早年毕业于安徽蚌埠医学院医疗系(77级)，同济医科大学硕士研究生(83级)，毕业后在同济医学院协和医院从事临床麻醉5年(86-91)。91-96年在美国新泽西罗格斯大学从事药物代谢与毒理机制的研究，对多种植物中的抗癌活性物质进行了药理评估。96年起先后在国际大型药物研究公司赛诺菲，先灵保雅和默沙东从事新型药物的靶点开发，候选药物的多层精选，临床前期的药理分析，体内代谢和多器官功能的毒理评估。参与多项生物标志物，转換医学和基因精准诊断的研发，首创双探针-三联针病理切片微小RNA肿瘤病理分型精准诊断。参与研究的原创药先后被FDA批准上市的有: 抗过敏药Claritin和Clarinex, 抗霉菌药Posaconazole, 降血脂药Zetia和Vytorin, 肌松药拮抗药Sugammadex, 抗丙肝病毒药Zepatier和新型免疫抗癌药Keytruda。发表研究论文和科普文章百余篇，新药专利2项。

业余爱好喜爱开园种菜，深海钓鱼，驱车旅游，科普写作，网球教学，扑克博奕，药物投资等。曾任同济医学院海外校友总会主席，参与多个海外团体的学术与交流活动。